← Leaderboards
Kun Cheng
University Of Missouri Kansas City
$8,618,981
Attributed
$8,618,981
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,618,981 · 6
By mechanism
R01$7,863,284 · 4
R21$755,697 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Biodistribution”
- Richard J. Whitley · University Of Alabama At Birmingham$37,499,995
- David Heimbrook · Leidos Biomedical Research, Inc.$28,845,920
- Steven H Liang · Emory University$24,468,532
- Michael Welch · Washington University$18,835,712
- Kamel Khalili · Temple University$17,758,009
- Xinhua Li · Nano Terra, Inc.$17,491,533
Research focus
BiodistributionIn VivoIn VitroUptakePeptidesLigandsBaseSmall Interfering RnaCellsSpecificityModificationVertebral ColumnSerumTargeted DeliveryGenesToxicologyRattusHepatic Stellate CellMolecular WeightExtracellular MatrixAnti-Pd-L1Collagen Type IProblem DrinkerLiver Fibrosis
Grant awards (29)
Normalizing PDAC stroma with PCBP2 siRNA nanoparticles to improve the antitumor activity of chemotherapy and immunotherapy$367,571
R01 · FY2025 · CA · contact PI
Normalizing PDAC stroma with PCBP2 siRNA nanoparticles to improve the antitumor activity of chemotherapy and immunotherapy$349,193
R01 · FY2024 · CA · contact PI
Normalizing PDAC stroma with PCBP2 siRNA nanoparticles to improve the antitumor activity of chemotherapy and immunotherapy$368,579
R01 · FY2023 · CA · contact PI
Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis$349,444
R01 · FY2022 · AA · contact PI
Development of a targeted delivery platform for checkpoint inhibitors$347,471
R01 · FY2022 · CA · contact PI
Development of a targeted delivery platform for checkpoint inhibitors$354,563
R01 · FY2021 · CA · contact PI
Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis$349,427
R01 · FY2021 · AA · contact PI
Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis$338,729
R01 · FY2021 · AA · contact PI
Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis$46,740
R01 · FY2021 · AA · contact PI
Development of a targeted delivery platform for checkpoint inhibitors$354,563
R01 · FY2020 · CA · contact PI
Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis$348,929
R01 · FY2020 · AA · contact PI
Peptide-based conjugate for a water-insoluble drug treating advanced prostate cancer$296,991
R01 · FY2020 · GM · contact PI
Peptide-based conjugate for a water-insoluble drug treating advanced prostate cancer$30,775
R01 · FY2020 · GM · contact PI
Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis$354,087
R01 · FY2019 · AA · contact PI
Development of a targeted delivery platform for checkpoint inhibitors$343,925
R01 · FY2019 · CA · contact PI
Peptide-based conjugate for a water-insoluble drug treating advanced prostate cancer$296,991
R01 · FY2019 · GM · contact PI
Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis$356,130
R01 · FY2018 · AA · contact PI
Development of a targeted delivery platform for checkpoint inhibitors$354,563
R01 · FY2018 · CA · contact PI
Peptide-based conjugate for a water-insoluble drug treating advanced prostate cancer$297,706
R01 · FY2018 · GM · contact PI
Peptide-based conjugate for a water-insoluble drug treating advanced prostate cancer$311,456
R01 · FY2017 · GM · contact PI
Targeted delivery of PCBP2 siRNA for treating alcoholic liver fibrosis$335,975
R01 · FY2016 · AA · contact PI
Targeted delivery of PCBP2 siRNA for treating alcoholic liver fibrosis$325,895
R01 · FY2015 · AA · contact PI
Targeted delivery of PCBP2 siRNA for treating alcoholic liver fibrosis$325,895
R01 · FY2014 · AA · contact PI
Targeted delivery of PCBP2 siRNA for treating alcoholic liver fibrosis$314,989
R01 · FY2013 · AA · contact PI
Targeted delivery of PCBP2 siRNA for treating alcoholic liver fibrosis$342,697
R01 · FY2012 · AA · contact PI
Targeted delivery of IKKalpha siRNA to prostate cancer cells$191,473
R21 · FY2011 · CA · contact PI
Treating Alcoholic Liver Fibrosis by Reversal of Type I Collagen$180,464
R21 · FY2010 · AA · contact PI
Targeted delivery of IKKalpha siRNA to prostate cancer cells$173,980
R21 · FY2010 · CA · contact PI
Treating Alcoholic Liver Fibrosis by Reversal of Type I Collagen$209,780
R21 · FY2009 · AA · contact PI